Thr286

Site Information
sCMHRQEtVDCLKKF SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 447797
Available spectra: 3 CST
Associated spectra: 3 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 6 , 22 ) , mass spectrometry ( 8 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 21 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 , 36 , 37 , 40 , 42 , 44 , 45 , 46 , 48 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 73 , 81 , 82 , 84 , 85 , 87 , 88 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 ) , mutation of modification site ( 2 , 5 , 6 , 9 , 22 , 34 , 38 , 43 , 76 , 79 , 104 ) , phospho-antibody ( 6 , 9 , 19 , 22 , 26 , 38 , 39 , 43 , 50 , 72 , 76 , 77 , 78 , 86 , 89 , 105 , 106 , 108 ) , western blotting ( 5 , 6 , 9 , 19 , 22 , 26 , 38 , 39 , 43 , 50 , 72 , 76 , 77 , 105 , 106 , 108 )
Disease tissue studied:	brain cancer ( 26 ) , glioblastoma ( 26 ) , glioma ( 26 ) , breast cancer ( 6 , 43 ) , colorectal cancer ( 19 ) , colorectal carcinoma ( 19 ) , gastric cancer ( 28 , 44 ) , gastric carcinoma ( 44 ) , leukemia ( 81 , 82 , 84 , 85 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 27 ) , acute megakaryoblastic leukemia (M7) ( 27 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 27 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 27 ) , acute myeloblastic leukemia, without maturation (M1) ( 27 ) , chronic lymphocytic leukemia ( 81 , 82 , 84 , 85 ) , lung cancer ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 21 , 35 , 44 , 45 , 73 , 95 , 100 , 102 , 103 ) , non-small cell lung cancer ( 13 , 14 , 15 , 17 , 18 , 21 , 24 , 25 , 35 , 45 , 73 , 103 ) , non-small cell lung cancer, surrounding tissue ( 46 ) , non-small cell lung adenocarcinoma ( 13 , 14 , 15 , 16 , 17 , 18 , 21 , 25 , 35 , 44 ) , non-small cell large cell lung carcinoma ( 14 , 17 ) , non-small cell squamous cell lung carcinoma ( 16 , 44 , 73 ) , small-cell lung cancer ( 11 , 12 ) , B cell lymphoma ( 27 ) , non-Hodgkin's lymphoma ( 27 ) , neuroblastoma ( 43 ) , multiple myeloma ( 27 , 39 ) , melanoma skin cancer ( 8 )
Relevant cell line - cell type - tissue:	'brain, cerebral cortex' ( 50 ) , 'brain, hippocampus' ( 5 ) , 'muscle, skeletal' ( 77 ) , 'neuron, cortical'-brain ( 22 ) , 'neuron, hippocampal, CA1 pyramidal' ( 2 ) , 293 (epithelial) ( 5 , 22 , 30 , 31 , 32 , 33 , 34 , 37 , 76 , 79 ) , A549 (pulmonary) ( 13 ) , AML-193 (monocyte) ( 27 ) , aorta ( 108 ) , B lymphoid-blood ( 81 , 82 , 84 , 85 ) , BE(2)-C (glial) ( 78 ) , C5N (keratinocyte) ( 76 ) , Cal-12T (pulmonary) ( 21 ) , Calu-3 (pulmonary) ( 15 ) , CLL23LB4 (B lymphocyte) ( 87 ) , CMK (megakaryoblast) ( 27 ) , CTS (myeloid) ( 27 ) , DMS153 (pulmonary) ( 18 ) , DMS53 (pulmonary) ( 12 ) , DMS79 (pulmonary) ( 11 ) , DOHH2 ('B lymphocyte, precursor') ( 27 ) , E.coli (bacterial) ( 2 , 9 , 38 ) , GM00130 (B lymphocyte) ( 40 ) , HCC15 (pulmonary) ( 16 ) , HCC44 (pulmonary) ( 21 ) , HCC78 (pulmonary) ( 17 ) , HCC827 (pulmonary) ( 15 ) , HCT116 (intestinal) ( 19 , 48 ) , HEK293T (epithelial) ( 22 , 104 ) , HEL (erythroid) ( 27 ) , HeLa (cervical) ( 36 ) , HUVEC (endothelial) ( 86 ) , Jurkat (T lymphocyte) ( 106 ) , Kasumi-1 (myeloid) ( 27 ) , KG-1 (myeloid) ( 27 ) , LOU-NH91 (squamous) ( 16 ) , lung ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 21 , 45 , 46 ) , MCF-7 (breast cell) ( 6 ) , MDA-MB-231 (breast cell) ( 6 , 43 ) , MEF (fibroblast) ( 9 ) , mesangial ( 105 ) , MKN-45 (gastric) ( 28 , 44 , 56 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 ) , MO1043 (B lymphocyte) ( 88 ) , MV4-11 (macrophage) ( 27 ) , myocyte-heart ( 72 ) , NCI-H128 (pulmonary) ( 11 ) , NCI-H1299 (pulmonary) ( 14 ) , NCI-H1355 (pulmonary) ( 13 ) , NCI-H1373 (pulmonary) ( 103 ) , NCI-H1417 (pulmonary) ( 11 ) , NCI-H1437 (pulmonary) ( 18 , 21 ) , NCI-H1650 (pulmonary) ( 15 ) , NCI-H1666 (pulmonary) ( 21 ) , NCI-H1703 (squamous) ( 16 , 44 , 51 , 52 , 53 , 54 , 55 , 73 ) , NCI-H1734 (pulmonary) ( 14 ) , NCI-H1781 (pulmonary) ( 17 ) , NCI-H1792 (pulmonary) ( 13 ) , NCI-H1944 (pulmonary) ( 14 ) , NCI-H1975 (pulmonary) ( 15 ) , NCI-H2073 (pulmonary) ( 16 , 18 ) , NCI-H209 (pulmonary) ( 11 , 18 ) , NCI-H2106 (pulmonary) ( 15 ) , NCI-H2228 (pulmonary) ( 17 , 25 ) , NCI-H23 (pulmonary) ( 13 ) , NCI-H2342 (pulmonary) ( 16 , 35 ) , NCI-H2405 (pulmonary) ( 21 ) , NCI-H3122 (pulmonary) ( 17 , 24 ) , NCI-H3255 (pulmonary) ( 44 , 57 , 58 , 59 , 60 ) , NCI-H358 (pulmonary) ( 14 ) , NCI-H441 (pulmonary) ( 13 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 ) , NCI-H446 (pulmonary) ( 12 ) , NCI-H460 (pulmonary) ( 14 ) , NCI-H524 (pulmonary) ( 11 ) , NCI-H526 (pulmonary) ( 12 ) , NCI-H661 (pulmonary) ( 17 ) , NCI-H69 (pulmonary) ( 12 ) , NCI-H82 (pulmonary) ( 12 ) , NCI-H838 (pulmonary) ( 18 ) , neuron-'brain, hippocampus' ( 79 ) , NT2 (testicular) ( 42 ) , OPM-2 (plasma cell) ( 27 ) , P31/FUJ (erythroid) ( 27 ) , RL ('B lymphocyte, precursor') ( 27 ) , RPMI-8266 (plasma cell) ( 27 ) , SF9 ( 9 ) , SH-SY5Y (neural crest) ( 43 ) , SU-DHL-6 (B lymphocyte) ( 27 ) , U-251 MG (glial) ( 26 ) , U266 (plasma cell) ( 27 , 39 ) , Vero (epithelial) ( 89 ) , WM239A (melanocyte) ( 8 )

Upstream Regulation
Regulatory protein:	PKCZ (human) ( 76 ) , TNF-R1 (human) ( 72 ) , TNF-R2 (human) ( 72 )
Putative in vivo kinases:	CAMK2A (human) ( 2 , 78 , 108 )
Kinases, in vitro:	CAMK2A (human) ( 1 , 38 , 49 , 74 , 75 , 83 )
Phosphatases, in vitro:	PPP1CA (human) ( 7 , 38 )
Treatments:	2-deoxyglucose ( 47 ) , AG1478 ( 86 ) , anti-TNFR1 ( 72 ) , anti-TNFR2 ( 72 ) , APV ( 50 ) , autocamtide_inhibitory_peptide ( 108 ) , BDNF ( 22 ) , bortezomib ( 39 ) , CTGF ( 105 ) , decorin ( 107 ) , etoposide ( 19 ) , exercise ( 77 ) , GDNF ( 78 ) , KN-93 ( 26 , 107 , 108 ) , MAFP ( 72 ) , monocular_deprivation ( 50 ) , phenylephrine ( 108 ) , phorbol_ester ( 76 ) , serum_starvation ( 78 ) , sleep ( 50 ) , thapsigargin ( 107 ) , thrombin ( 86 ) , tiron ( 19 ) , TNF ( 72 ) , virus infection ( 26 , 89 )

Downstream Regulation
Effects of modification on CAMK2A:	enzymatic activity, induced ( 1 , 80 , 89 , 104 ) , intracellular localization ( 79 ) , molecular association, regulation ( 2 , 22 , 34 , 43 ) , protein conformation ( 2 , 80 )
Effects of modification on biological processes:	cell growth, altered ( 43 ) , cell growth, induced ( 6 ) , cell motility, induced ( 6 )
Induce interaction with:	GIT1 (mouse) ( 22 ) , MAP2 (human) ( 43 ) , NMDAR2B (human) ( 2 , 34 )
Inhibit interaction with:	MBP (human) ( 43 ) , neurogranin (human) ( 43 )

Disease / Diagnostics Relevance
Relevant diseases:	breast cancer ( 6 )

References
1	Brown CN, et al. (2021) Characterization of six CaMKIIα variants found in patients with schizophrenia. iScience 24, 103184 34667946 Curated Info
2	Hosokawa T, et al. (2021) CaMKII activation persistently segregates postsynaptic proteins via liquid phase separation. Nat Neurosci 33927400 Curated Info
3	Xu D, et al. (2021) Identification and Characterization of TF-lncRNA Regulatory Networks Involved in the Tumorigenesis and Development of Adamantinomatous Craniopharyngioma. Front Oncol 11, 739714 35155179 Curated Info
4	Gallego-Selles A, et al. (2020) Regulation of Nrf2/Keap1 signalling in human skeletal muscle during exercise to exhaustion in normoxia, severe acute hypoxia and post-exercise ischaemia: Influence of metabolite accumulation and oxygenation. Redox Biol 36, 101627 32863217 Curated Info
5	Goodell DJ, et al. (2017) DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Rep 19, 2231-2243 28614711 Curated Info
6	Chi M, et al. (2016) Phosphorylation of calcium/calmodulin-stimulated protein kinase II at T286 enhances invasion and migration of human breast cancer cells. Sci Rep 6, 33132 27605043 Curated Info
7	Mayadevi M, et al. (2016) Protection of α-CaMKII from Dephosphorylation by GluN2B Subunit of NMDA Receptor Is Abolished by Mutation of Glu96 or His282 of α-CaMKII. PLoS One 11, e0162011 27610621 Curated Info
8	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
9	Kawaai K, et al. (2015) IRBIT regulates CaMKIIα activity and contributes to catecholamine homeostasis through tyrosine hydroxylase phosphorylation. Proc Natl Acad Sci U S A 112, 5515-20 25922519 Curated Info
10	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
11	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
12	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
13	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
14	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
15	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
16	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
17	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
18	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
19	Sen N, Kumari R, Singh MI, Das S (2013) HDAC5, a key component in temporal regulation of p53-mediated transactivation in response to genotoxic stress. Mol Cell 52, 406-20 24120667 Curated Info
20	Kim SS, Benchimol S (2013) HDAC5--a critical player in the p53 acetylation network. Mol Cell 52, 289-90 24207022 Curated Info
21	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
22	Zhang Z, et al. (2013) G-protein-coupled receptor kinase interactor-1 serine 419 accelerates premature synapse formation in cortical neurons by interacting with Ca(2+)/calmodulin-dependent protein kinase IIβ. Brain Res Bull 95, 70-7 23352984 Curated Info
23	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
24	Rikova K (2013) CST Curation Set: 18531; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS/T) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759 Curated Info
25	Rikova K (2013) CST Curation Set: 18529; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS/T) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759 Curated Info
26	Haolong C, et al. (2013) Enterovirus 71 VP1 activates calmodulin-dependent protein kinase II and results in the rearrangement of vimentin in human astrocyte cells. PLoS One 8, e73900 24073199 Curated Info
27	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
28	Rikova K (2012) CST Curation Set: 16149; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS/T) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759 Curated Info
29	Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
30	Mulhern D (2011) CST Curation Set: 12822; Year: 2011; Biosample/Treatment: cell line, HEK 293/ku-0063794; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
31	Mulhern D (2011) CST Curation Set: 12831; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
32	Mulhern D (2011) CST Curation Set: 12847; Year: 2011; Biosample/Treatment: cell line, HEK 293/WYE-354; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
33	Mulhern D (2011) CST Curation Set: 12891; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
34	O'Leary H, et al. (2011) Nucleotides and Phosphorylation Bi-directionally Modulate Ca2+/Calmodulin-dependent Protein Kinase II (CaMKII) Binding to the N-Methyl-D-aspartate (NMDA) Receptor Subunit GluN2B. J Biol Chem 286, 31272-81 21768120 Curated Info
35	Rikova K (2011) CST Curation Set: 10886; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
36	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
37	Goswami T, Ballif B. (2011) Methods for the Isolation of Phosphoproteins and Phosphopeptides for Mass Spectrometry Analysis: Toward Increased Functional Phosphoproteomics Curated Info
38	Cheriyan J, et al. (2011) Calcium/calmodulin dependent protein kinase II bound to NMDA receptor 2B subunit exhibits increased ATP affinity and attenuated dephosphorylation. PLoS One 6, e16495 21423658 Curated Info
39	Ge F, et al. (2010) Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells. PLoS One 5 20927383 Curated Info
40	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
41	Coultrap SJ, et al. (2010) CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem 285, 17930-7 20353941 Curated Info
42	Zhou J (2010) CST Curation Set: 9667; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
43	Skelding KA, et al. (2010) Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function. Cell Signal 22, 759-769 20060891 Curated Info
44	Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64 20736484 Curated Info
45	Rikova K (2009) CST Curation Set: 7888; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
46	Rikova K (2009) CST Curation Set: 7632; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
47	Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33 19574224 Curated Info
48	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info
49	Pradeep KK, et al. (2009) Regulation of Ca2+/calmodulin-dependent protein kinase II catalysis by N-methyl-D-aspartate receptor subunit 2B. Biochem J 419, 123-32, 4 p following 132 19086921 Curated Info
50	Aton SJ, et al. (2009) Mechanisms of sleep-dependent consolidation of cortical plasticity. Neuron 61, 454-66 19217381 Curated Info
51	Moritz A (2009) CST Curation Set: 5885; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
52	Moritz A (2009) CST Curation Set: 5877; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
53	Moritz A (2009) CST Curation Set: 5879; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
54	Moritz A (2009) CST Curation Set: 5882; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
55	Moritz A (2009) CST Curation Set: 5875; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
56	Moritz A (2008) CST Curation Set: 5777; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
57	Moritz A (2008) CST Curation Set: 5660; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
58	Moritz A (2008) CST Curation Set: 5651; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
59	Moritz A (2008) CST Curation Set: 5654; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
60	Moritz A (2008) CST Curation Set: 5657; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
61	Moritz A (2008) CST Curation Set: 5523; Year: 2008; Biosample/Treatment: cell line, MKN-45/rapamycin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
62	Moritz A (2008) CST Curation Set: 5527; Year: 2008; Biosample/Treatment: cell line, MKN-45/U 0126; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
63	Moritz A (2008) CST Curation Set: 5515; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
64	Moritz A (2008) CST Curation Set: 5519; Year: 2008; Biosample/Treatment: cell line, MKN-45/wortmannin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
65	Moritz A (2008) CST Curation Set: 5380; Year: 2008; Biosample/Treatment: cell line, MKN-45/wortmannin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
66	Moritz A (2008) CST Curation Set: 5010; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS/T) Immunoaffinity Beads Cat#: 1979 Curated Info
67	Rush J (2008) CST Curation Set: 4496; Year: 2008; Biosample/Treatment: cell line, MKN-45/untreated &'\|\|' normal; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
68	Rush J (2008) CST Curation Set: 4484; Year: 2008; Biosample/Treatment: cell line, MKN-45/untreated &'\|\|' normal; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
69	Rush J (2008) CST Curation Set: 4492; Year: 2008; Biosample/Treatment: cell line, MKN-45/untreated &'\|\|' normal; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
70	Rush J (2008) CST Curation Set: 4488; Year: 2008; Biosample/Treatment: cell line, MKN-45/untreated &'\|\|' normal; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
71	Moritz A (2007) CST Curation Set: 3609; Year: 2007; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
72	Defer N, Azroyan A, Pecker F, Pavoine C (2007) TNFR1 and TNFR2 signaling interplay in cardiac myocytes. J Biol Chem 282, 35564-73 17913704 Curated Info
73	Moritz A (2007) CST Curation Set: 3536; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
74	Vest RS, et al. (2007) Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell 18, 5024-33 17942605 Curated Info
75	Robison AJ, Winder DG, Colbran RJ, Bartlett RK (2007) Oxidation of calmodulin alters activation and regulation of CaMKII. Biochem Biophys Res Commun 356, 97-101 17343827 Curated Info
76	Perfetti A, et al. (2007) Phorbol esters induce intracellular accumulation of the anti-apoptotic protein PED/PEA-15 by preventing ubiquitinylation and proteasomal degradation. J Biol Chem 282, 8648-57 17227770 Curated Info
77	Rose AJ, Kiens B, Richter EA (2006) Ca2+-calmodulin-dependent protein kinase expression and signalling in skeletal muscle during exercise. J Physiol 574, 889-903 16690701 Curated Info
78	Kobori N, Moore AN, Dash PK (2006) GDNF abates serum deprivation-induced tyrosine hydroxylase Ser19 phosphorylation and activity. Brain Res 1086, 142-51 16626642 Curated Info
79	Bayer KU, et al. (2006) Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci 26, 1164-74 16436603 Curated Info
80	Rosenberg OS, et al. (2005) Structure of the autoinhibited kinase domain of CaMKII and SAXS analysis of the holoenzyme. Cell 123, 849-60 16325579 Curated Info
81	Goss V (2005) CST Curation Set: 1036; Year: 2005; Biosample/Treatment: blood, B lymphoid/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
82	Goss V (2005) CST Curation Set: 1037; Year: 2005; Biosample/Treatment: blood, B lymphoid/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
83	Robison AJ, Bartlett RK, Bass MA, Colbran RJ (2005) Differential modulation of Ca2+/calmodulin-dependent protein kinase II activity by regulated interactions with N-methyl-D-aspartate receptor NR2B subunits and alpha-actinin. J Biol Chem 280, 39316-23 16172120 Curated Info
84	Goss V (2005) CST Curation Set: 1009; Year: 2005; Biosample/Treatment: blood, B lymphoid/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
85	Goss V (2005) CST Curation Set: 1010; Year: 2005; Biosample/Treatment: blood, B lymphoid/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
86	David-Dufilho M, et al. (2005) Endothelial thrombomodulin induces Ca2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II. J Biol Chem 280, 35999-6006 16126727 Curated Info
87	Goss V (2005) CST Curation Set: 939; Year: 2005; Biosample/Treatment: cell line, CLL23LB4/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
88	Goss V (2005) CST Curation Set: 940; Year: 2005; Biosample/Treatment: cell line, M01043/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
89	Stefanovic S, et al. (2005) Vimentin rearrangement during African swine fever virus infection involves retrograde transport along microtubules and phosphorylation of vimentin by calcium calmodulin kinase II. J Virol 79, 11766-75 16140754 Curated Info
90	Moritz A (2005) CST Curation Set: 790; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
91	Moritz A (2005) CST Curation Set: 791; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
92	Moritz A (2005) CST Curation Set: 792; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
93	Moritz A (2005) CST Curation Set: 793; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
94	Moritz A (2005) CST Curation Set: 794; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
95	Moritz A (2005) CST Curation Set: 795; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
96	Moritz A (2005) CST Curation Set: 796; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
97	Moritz A (2005) CST Curation Set: 797; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
98	Moritz A (2005) CST Curation Set: 798; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
99	Moritz A (2005) CST Curation Set: 799; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
100	Moritz A (2005) CST Curation Set: 782; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
101	Moritz A (2005) CST Curation Set: 783; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
102	Moritz A (2005) CST Curation Set: 706; Year: 2005; Biosample/Treatment: cell line, NCI-H441/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
103	Moritz A (2005) CST Curation Set: 707; Year: 2005; Biosample/Treatment: cell line, NCI-H1373/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
104	Sessoms-Sikes S, Honse Y, Lovinger DM, Colbran RJ (2005) CaMKIIalpha enhances the desensitization of NR2B-containing NMDA receptors by an autophosphorylation-dependent mechanism. Mol Cell Neurosci 29, 139-47 15866054 Curated Info
105	Wahab NA, Weston BS, Mason RM (2005) Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 16, 340-51 15601748 Curated Info
106	Chan SM, et al. (2004) Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 10, 1390-6 15558056 Curated Info
107	Abdel-Wahab N, Wicks SJ, Mason RM, Chantry A (2002) Decorin suppresses transforming growth factor-beta-induced expression of plasminogen activator inhibitor-1 in human mesangial cells through a mechanism that involves Ca2+-dependent phosphorylation of Smad2 at serine-240. Biochem J 362, 643-9 11879191 Curated Info
108	Munevar S, et al. CaMKIIT287 and T305 regulate history-dependent increases in alpha agonist-induced vascular tone. J Cell Mol Med 12, 219-26 18088385 Curated Info